FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130833499> ?p ?o ?g. }

• W2130833499 endingPage "763" @default.
• W2130833499 startingPage "755" @default.
• W2130833499 abstract "Hypertensive heart disease is a major contributor to cardiovascular mortality. Endothelin is a potent vasoconstrictive and profibrotic mediator produced by the endothelin-converting enzyme (ECE), whereas natriuretic peptides, degraded by the neutral endopeptidase (NEP), have diuretic, vasodilatory, and antifibrotic properties. Thus, combined ECE/NEP inhibition may halt hypertensive cardiac remodeling. This study examined effects of SLV338, a novel ECE/NEP inhibitor, on cardiac protection in experimental renovascular hypertension (2-kidney, 1-clip [2K1C]). Male rats were allocated to 5 groups: sham-operated rats, untreated animals with 2K1C, 2K1C animals treated with oral SLV338 (30 and 100 mg/kg per day), and 2K1C animals treated with oral losartan (20 mg/kg per day). Treatment duration was 12 weeks. Blood pressure was assessed every 4 weeks. At study end, hearts were taken for histology/computer-aided histomorphometry/immunohistochemistry. Pharmacological properties of SLV338 are described. SLV338 is a dual ECE/NEP inhibitor, as demonstrated both in vitro and in vivo. In the 2K1C study, losartan lowered blood pressure by ≤46 mm Hg, whereas both dosages of SLV338 had no effect. However, SLV338 (both dosages) completely normalized cardiac interstitial fibrosis, perivascular fibrosis, myocyte diameter, and media:lumen ratio of cardiac arteries, as did losartan. Cardiac transforming growth factor-β1 expression was significantly enhanced in untreated 2K1C rats versus controls, whereas treatment with SLV338 and losartan prevented this effect. Taken together, dual ECE/NEP inhibitor SLV338 prevents cardiac remodeling to the same extent as losartan, but in a blood pressure-independent manner, in a rat model of renovascular hypertension. This effect is at least partially mediated via suppression of cardiac transforming growth factor-β1 expression." @default.
• W2130833499 created "2016-06-24" @default.
• W2130833499 creator A5001841343 @default.
• W2130833499 creator A5004040780 @default.
• W2130833499 creator A5007484586 @default.
• W2130833499 creator A5010304788 @default.
• W2130833499 creator A5017332628 @default.
• W2130833499 creator A5022687335 @default.
• W2130833499 creator A5026754112 @default.
• W2130833499 creator A5050709034 @default.
• W2130833499 creator A5051629956 @default.
• W2130833499 creator A5059070828 @default.
• W2130833499 creator A5082183114 @default.
• W2130833499 creator A5090379669 @default.
• W2130833499 date "2011-04-01" @default.
• W2130833499 modified "2023-10-03" @default.
• W2130833499 title "Endothelin-Converting Enzyme/Neutral Endopeptidase Inhibitor SLV338 Prevents Hypertensive Cardiac Remodeling in a Blood Pressure–Independent Manner" @default.
• W2130833499 cites W137536100 @default.
• W2130833499 cites W1533862150 @default.
• W2130833499 cites W1992666213 @default.
• W2130833499 cites W1998137947 @default.
• W2130833499 cites W2031012006 @default.
• W2130833499 cites W2043346058 @default.
• W2130833499 cites W2057386289 @default.
• W2130833499 cites W2057508448 @default.
• W2130833499 cites W2065254627 @default.
• W2130833499 cites W2072591618 @default.
• W2130833499 cites W2075100686 @default.
• W2130833499 cites W2076293103 @default.
• W2130833499 cites W2078016545 @default.
• W2130833499 cites W2094988613 @default.
• W2130833499 cites W2130196477 @default.
• W2130833499 cites W2136145230 @default.
• W2130833499 cites W2140909944 @default.
• W2130833499 cites W2144360877 @default.
• W2130833499 cites W2167004336 @default.
• W2130833499 cites W2322134991 @default.
• W2130833499 cites W2325687453 @default.
• W2130833499 cites W2428411855 @default.
• W2130833499 cites W4229755335 @default.
• W2130833499 cites W846607674 @default.
• W2130833499 cites W2132602077 @default.
• W2130833499 doi "https://doi.org/10.1161/hypertensionaha.110.163972" @default.
• W2130833499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21339476" @default.
• W2130833499 hasPublicationYear "2011" @default.
• W2130833499 type Work @default.
• W2130833499 sameAs 2130833499 @default.
• W2130833499 citedByCount "37" @default.
• W2130833499 countsByYear W21308334992012 @default.
• W2130833499 countsByYear W21308334992013 @default.
• W2130833499 countsByYear W21308334992014 @default.
• W2130833499 countsByYear W21308334992015 @default.
• W2130833499 countsByYear W21308334992016 @default.
• W2130833499 countsByYear W21308334992017 @default.
• W2130833499 countsByYear W21308334992018 @default.
• W2130833499 countsByYear W21308334992019 @default.
• W2130833499 countsByYear W21308334992021 @default.
• W2130833499 crossrefType "journal-article" @default.
• W2130833499 hasAuthorship W2130833499A5001841343 @default.
• W2130833499 hasAuthorship W2130833499A5004040780 @default.
• W2130833499 hasAuthorship W2130833499A5007484586 @default.
• W2130833499 hasAuthorship W2130833499A5010304788 @default.
• W2130833499 hasAuthorship W2130833499A5017332628 @default.
• W2130833499 hasAuthorship W2130833499A5022687335 @default.
• W2130833499 hasAuthorship W2130833499A5026754112 @default.
• W2130833499 hasAuthorship W2130833499A5050709034 @default.
• W2130833499 hasAuthorship W2130833499A5051629956 @default.
• W2130833499 hasAuthorship W2130833499A5059070828 @default.
• W2130833499 hasAuthorship W2130833499A5082183114 @default.
• W2130833499 hasAuthorship W2130833499A5090379669 @default.
• W2130833499 hasConcept C104826730 @default.
• W2130833499 hasConcept C126322002 @default.
• W2130833499 hasConcept C134018914 @default.
• W2130833499 hasConcept C144980905 @default.
• W2130833499 hasConcept C149601957 @default.
• W2130833499 hasConcept C170493617 @default.
• W2130833499 hasConcept C181199279 @default.
• W2130833499 hasConcept C185592680 @default.
• W2130833499 hasConcept C27016395 @default.
• W2130833499 hasConcept C2777420927 @default.
• W2130833499 hasConcept C2779611605 @default.
• W2130833499 hasConcept C2780288358 @default.
• W2130833499 hasConcept C2780559512 @default.
• W2130833499 hasConcept C2781243531 @default.
• W2130833499 hasConcept C2908929049 @default.
• W2130833499 hasConcept C3018763269 @default.
• W2130833499 hasConcept C55493867 @default.
• W2130833499 hasConcept C71924100 @default.
• W2130833499 hasConcept C84393581 @default.
• W2130833499 hasConceptScore W2130833499C104826730 @default.
• W2130833499 hasConceptScore W2130833499C126322002 @default.
• W2130833499 hasConceptScore W2130833499C134018914 @default.
• W2130833499 hasConceptScore W2130833499C144980905 @default.
• W2130833499 hasConceptScore W2130833499C149601957 @default.
• W2130833499 hasConceptScore W2130833499C170493617 @default.
• W2130833499 hasConceptScore W2130833499C181199279 @default.
• W2130833499 hasConceptScore W2130833499C185592680 @default.
• W2130833499 hasConceptScore W2130833499C27016395 @default.

• next